Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 17/20 | 1.00 |
| ▸ | PIK3CB | P42338 | 12/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 11/20 | 1.00 |
| ▸ | PIK3CG | P48736 | 11/20 | 1.00 |
| ▸ | MTOR | P42345 | 11/20 | 1.00 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.60 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17708290 | 0.84 | PIK3CA (0.73) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL10100315 | 0.84 | PIK3R1 (1.00) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL16882231 | 0.83 | PIK3CA (0.71) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL16882227 | 0.83 | PIK3CA (0.72) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL10092215 | 0.82 | PIK3R1 (1.00) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL14725945 | 0.82 | PIK3R1 (1.00) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL15603048 | 0.81 | PIK3R1 (0.93) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL15602961 | 0.80 | PIK3R1 (0.78) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL14725986 | 0.79 | PIK3R1 (0.66) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG | |
| SCHEMBL2146849 | 0.79 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2526102-B1 | Inhibitors of PI3 kinase | FUNDACIÓN CENTRO NAC DE INVESTIG ONCOLÓGICAS CARLOS III (ES) | 2017-03-08 | — | — | EP | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| US-9073927-B2 | Inhibitors of PI3 kinase | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) | 2015-07-07 | — | — | US | disclosed |
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053371-A1 | INHIBITORS OF PI3 KINASE | PIK3CA, MTOR, PIK3C2A | PIK3CA 1/4885PIK3R1 28/4885PIK3CB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.